Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$961.26
Open:$956.28
Day's Low:$953.00
Day's High:$975.49
Bid / Ask:-
Market Cap:100.69B
Enterprise Value:89.87B
52-Week Range
52-Week Low:$591.52
52-Week High:$975.49
Current position in 52-week range
52w Low-52w High
50-Day Avg:$795.85
200-Day Avg:$738.63
Volume
Volume Today:1,198,080
Avg Volume (3m):746,726
Avg Volume (10d):958,860
52-Week Change:+53.07%
vs S&P 500, 52 weeks:-
Beta:0.10
Valuation Multiples
P/E (trailing):21.49
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
P/E (forward):13.79
PEG Ratio:1.64
Price / Book:2.91
Price / Sales (TTM):5.96
EV / Revenue:5.32
EV / EBITDA:15.92
Dividends
Current yield:0.39%
Annual Dividend Rate:$3.76
Dividend Trailing:$3.70
Yield Trailing:0.38%
5-Year Avg Yield:-
Payout Ratio:8.18%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):16.90B
Gross Profit:7.90B
EBITDA:5.65B
Net Income (TTM):4.82B
Rev Growth (YoY):+36.30%
Earnings Growth (YoY):+35.50%
Quarterly earnings growth (YoY):+33.50%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$45.30
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$70.61
Revenue Per Share:$164.24
Cash Per Share:-
Book Value:$333.93
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:9.30B
Total Debt:2.71B
Net Debt (Debt - Cash):−6.59B (net cash)
Debt / Equity:8.08%
Current Ratio:3.35
Quick Ratio:2.72
Cash Flows
Operating Cash Flow:4.85B
Free Cash Flow (FCF):2.58B
FCF Yield (FCF / Market Cap):-
Enterprise Value:89.87B
EV / Revenue:5.32
EV / EBITDA:15.92
Profitability
ROE (Return on Equity):14.95%
ROA (Return on Assets):7.59%
P/E (trailing):21.49
P/E (forward):13.79
Price / Book:2.91
PEG Ratio:1.64
52-Week Change:+53.07%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$45.30
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$70.61
P/E (forward):13.79
PEG Ratio:1.64
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$164.24
Cash Per Share:-
Book Value:$333.93
Cash Flows (TTM)
Free Cash Flow:2.58B
Operating Cash Flow:4.85B
EBITDA:5.65B
Total Revenue (TTM):16.90B
Net Income (TTM):4.82B
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:101,630,713
Float (free shares):96,322,906
Short interest (shares):2,134,934
Short % of float:-
Short Ratio (days to cover):2.78
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Regeneron Pharmaceuticals, Inc. (REGN) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Executive VP of Research & Co-Chief Scientific Officer
67
1.73M
Mr. Daniel P. Van Plew
Executive VP and GM of Industrial Operations & Product Supply
52
2.03M
Mr. Rajesh Ahuja
Senior Vice President of Quality Assurance & Operations
-
-
Mr. Ryan Steinberger
Executive VP, Chief Digital & Technology Officer
-
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
Regeneron Pharmaceuticals, Inc. (REGN): Quantitative Analysis
Regeneron Pharmaceuticals, Inc. (REGN) — Healthcare — Biotechnology. REGN is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, REGN has returned +26.5% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
REGN ranks 192 of 461 on today's multifactor score, and 25 of the 55 Healthcare companies that score. Its strongest factor is quality (Z 0.40, ranked 92 of 468); its weakest is value (Z -0.20, ranked 263 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
Frequently asked questions about Regeneron Pharmaceuticals (REGN)
When does Regeneron Pharmaceuticals report earnings?
Regeneron Pharmaceuticals has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Oct 30, 2026). REGN earnings dates and times, quarter by quarter →
What is Regeneron Pharmaceuticals's P/E ratio?
Regeneron Pharmaceuticals's P/E (price over earnings per share for the last twelve months) is 21.5 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Regeneron Pharmaceuticals is below its sector median. Healthcare stocks, company by company →
Where does Regeneron Pharmaceuticals rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Regeneron Pharmaceuticals ranks 192 of 461, and 25 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Regeneron Pharmaceuticals insiders bought or sold shares?
SEC Form 4 shows no open-market purchase of Regeneron Pharmaceuticals shares from August 2025 through Nov 3, 2026. The latest sale was on Oct 14, 2026, by an officer, for $3.2M. In total, from August 2025 through Nov 3, 2026: 0 purchases and 17 sales by directors, officers and large shareholders. All REGN insider trades →
Does Regeneron Pharmaceuticals pay a dividend?
Yes. Its dividend yield is 0.39% at the Nov 3, 2026 close (annual dividend of $3.76 per share). The next announced ex-dividend date is Nov 20, 2026.
What sector is Regeneron Pharmaceuticals in, and which index?
Regeneron Pharmaceuticals is classified in the Healthcare sector (industry: Biotechnology), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.